Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 29, 2025 09:45 ET | Source: SNS Insider pvt ltd

AI in Precision Medicine Market to Reach USD 18.27 Billion by 2032, Driven by AI-Powered Diagnostics and Personalized Treatment Advances – SNS Insider

Austin, Oct. 29, 2025 (GLOBE NEWSWIRE) -- AI in Precision Medicine Market Size & Growth Analysis According to SNS Insider, the global AI in Precision Medicine Market was valued at USD 1.80...
October 10, 2025 08:00 ET | Source: Precedence Research

Generative AI in the Drug Discovery Market Size to Attain USD 2847.43 Million, Rising at 27.42% CAGR by 2034

Ottawa, Oct. 10, 2025 (GLOBE NEWSWIRE) -- The global generative AI in drug discovery market size was valued at USD 250 million in 2024 and is predicted to hit around USD 2847.43 million by 2034,...
September 29, 2025 08:00 ET | Source: MindRank AI Ltd.

MindRank Announces Positive 12-week Once-Daily (QD) Results for AI-Designed Oral GLP-1 Agonist MDR-001 in Adults with Obesity

Using an optimized once-daily (QD) regimen, MDR-001 achieved a body weight reduction of 8.9% over 12 weeks.
September 18, 2025 08:00 ET | Source: MindRank AI Ltd.

MindRank Presented Clinical Update on Oral GLP-1RA MDR-001 at LSX World Congress, Highlighting AI-Powered Innovation

Mindrank delivered a keynote presentation entitled “AI-Designed Oral GLP-1RA: First-in-Class Phase IIb Clinical Readouts and Translational Insights”.
July 10, 2025 08:00 ET | Source: e-therapeutics plc

e-therapeutics De-risks Clinical Path for GalOmic Candidate ETX-312 with Positive Non-clinical Data

ETX-312 well tolerated at exaggerated dose levels in GLP-compliant toxicology studies GMP manufacturing of clinical trial batch successfully completed On track for CTA submission in Q4 2025 ...
June 24, 2025 08:00 ET | Source: MindRank AI Ltd.

MindRank Announces Positive Phase 2b Results for AI-Designed Oral GLP-1 Receptor Agonist MDR-001 in Adults with Obesity or Overweight

MDR-001 achieved statistically significant weight reductions of 8.2% to 10.3% at 24 weeks compared to 2.5% with placebo (p<0.00001), with up to 48.1% of participants achieving ≥10% weight loss.No...
May 15, 2025 08:00 ET | Source: Pathos AI

Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-driven biotech company applying cutting-edge artificial intelligence to drug development, today announced its $365 million Series D...
May 08, 2025 08:00 ET | Source: Pathos AI

Pathos AI Appoints Iker Huerga as Chief Executive Officer to Lead the Next Era of AI-Enabled Drug Development

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-enabled biotech company focused on transforming drug development in oncology, today announced the appointment of Iker Huerga as...
March 07, 2025 08:00 ET | Source: MindRank

Dual WEE1/YES1 Kinase Inhibitor MRANK-106 Secures FDA IND Clearance, Positioning MindRank in First-in-Class Oncology Pipeline

HANGZHOU, China and LONDON, March 07, 2025 (GLOBE NEWSWIRE) -- MindRank, a clinical stage artificial intelligence (AI)-empowered drug discovery company, announces today that the U.S. Food and Drug...
May 15, 2023 13:34 ET | Source: InSilico Medicine

Insilico Medicine Appoints Michael Bayewitch as VP, Business Development and Strategy

Abu Dhabi, May 15, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has appointed Michael Bayewitch, PhD, as Vice...